Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intercept Pharmaceuticals
Biotech
Ipsen, Genfit report phase 3 rare liver disease success
The partners plan to seek U.S. and European approvals of elafibranor, their rival to Intercept’s Ocaliva, in primary biliary cholangitis.
Nick Paul Taylor
Jun 30, 2023 6:15am
Enanta pulls plug on NASH, seeks to offload assets for combos
Oct 4, 2021 8:40am
Ex-Intercept CMO Campagna lands at Q32
Mar 9, 2021 8:45am
Intercept loses chief medical officer months after CEO's exit
Feb 23, 2021 7:20am
CymaBay tees up new phase 3 study for resurrected liver drug
Nov 16, 2020 8:04pm
After disastrous NASH crash, Genfit slashes jobs and splits ops
Oct 1, 2020 7:45am
